… vivo by one or more of the mouse Oatp1a/1b transporters, but we observed no contribution
of human OATP1B1 … in order to assess whether transgenic OATP1B1 and OATP1B3 do or do …

… The inhibitory effect of 146 drugs and drug-like compounds on OATP1B1-mediated transport
was studied in HEK293 cells. A computational model was developed to predict OATP1B1 …

… inhibition of human OATP1B1. Apparent K m values for the … an OATP1B1-mediated DDI
in vivo and that a clinical interaction study is warranted to confirm whether AZX is an OATP1B1 …

… potent OATP1B1 inhibitors cause clinical drug–drug interactions, … vitro data are in line with
that prior knowledge in that sorafenib was found to be an inhibitor for both human OATP1B1 …

… various anionic drugs and as a site of drug-drug interactions (… of the in vitro approaches used
to predict human hepatic … for OATP1B1, requiring an appropriate selection of in vitro probe …

… In vitro and in vivo studies have shown that some drugs inhibit these transporters and
cause clinically relevant drug–drug interactions (DDIs). Among these drugs, cyclosporin A …

… Most in vivo evidence for intestinal OATP2B1 as a mediator of oral absorption comes from
… , but not OATP1B1/OATP1B3, and that uptake of erlotinib in the liver of human subjects is …

… in human OATP1B1- and OATP1B3-transfected human embryonic kidney 293 (HEK293)
cells with estradiol-17β-glucuronide as a probe (2- and 3-fold increase in potency; details in …

… Provided the importance of OATP1B1 and OATP1B3 in the hepatic disposition of drugs, it
is essential to have in vitro assays to assess potential drug–drug interactions early in …

… relevant drug–drug interactions with substrates of BCRP, OATP1B1, or … suggested by in
vitro findings was not confirmed in vivo. … , prompts additional in vivo studies in human subjects. …